These results indicated that the HER2-LsbMDDs not only enhanced the targeting to the tumor site resulting in a higher accumulation of DTX in the tumor, but also further retained the DTX in the tumor for a longer time to improve the therapeutic efficacy. This evidence concerns the gene ERBB2 and neoplasm.